QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising ClinicalStage Metastatic and Primary Bone Cancer Treatment CycloSam

Austin, TX and Lake Zurich, IL, May 16, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for…Read More